Anebulo Pharmaceuticals Files 8-K
Ticker: ANEB · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1815974
| Field | Detail |
|---|---|
| Company | Anebulo Pharmaceuticals, Inc. (ANEB) |
| Form Type | 8-K |
| Filed Date | Dec 22, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $3.50, $1,050,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
TL;DR
Anebulo Pharma filed an 8-K on 12/22/25. Check for updates.
AI Summary
Anebulo Pharmaceuticals, Inc. filed an 8-K on December 22, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
Why It Matters
This 8-K filing indicates a regulatory update from Anebulo Pharmaceuticals, Inc., which could contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate indication of significant financial or operational changes.
Key Players & Entities
- Anebulo Pharmaceuticals, Inc. (company) — Registrant
- December 22, 2025 (date) — Date of earliest event reported
- 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734 (location) — Address of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for 'Other Events' and 'Financial Statements and Exhibits' for Anebulo Pharmaceuticals, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 22, 2025.
What is the principal executive office address for Anebulo Pharmaceuticals, Inc.?
The principal executive office address is 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the SIC code for Anebulo Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Anebulo Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,019 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2025-12-22 09:00:34
Key Financial Figures
- $0.001 — 0 shares of its common stock, par value $0.001 per share (the "Common Stock"), at a pu
- $3.50 — "Common Stock"), at a purchase price of $3.50 per share, less any applicable withhold
- $1,050,000 — or an aggregate purchase price of up to $1,050,000. The cash tender offer is being underta
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-028676.txt ( ) — 240KB
- aneb-20251222.xsd (EX-101.SCH) — 3KB
- aneb-20251222_lab.xml (EX-101.LAB) — 33KB
- aneb-20251222_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANEBULO PHARMACEUTICALS, INC. Date: December 22, 2025 By: /s/ Richard Anthony Cunningham Richard Anthony Cunningham Chief Executive Officer and Interim Chief Financial Officer -3-